OOIR: Observatory of International Research

Papers

(The median citation count of Current Hematologic Malignancy Reports is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations	171
Targeting RUNX1 Germline Variants: Agents Under Investigation	36
Monoclonal Gammopathy-Associated Neuropathy	27
Financial Toxicity in Patients with Hematologic Malignancies: a Review and Need for Interventions	25
Contemporary Updates in the Prevention and Treatment of Graft-Versus-Host Disease	22
Management of Chronic Myeloid Leukemia in Children and Young Adults	22
Telomere Biology Disorder: A Focus on Gastrointestinal and Hepatic Manifestations	20
Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications	20
Correction to: Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities	20
Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer	19
Value in Myeloma Care: Myth or Reality	19
Splicing Factor Mutations in Chronic Myelomonocytic Leukemia: Biological Consequences and Therapeutic Implications	19
Transplantation and Cellular Therapy for Older Adults—The MSK Approach	18
Allogeneic Transplant for CMML	18
How Do We Manage Chronic Lymphocytic Leukemia in India	15
Prognostic and Predictive Models in Myelofibrosis	15
Multiple Myeloma: Current Clinical Landscape and Compounding Costs	14
New Molecular and Biological Markers in Cutaneous T Cell Lymphoma: Therapeutic Implications	13
Novel Approaches to Managing Patients with Relapsed and Refractory Waldenström Macroglobulinemia	13
Diagnosis and Management of Pulmonary Manifestations of Telomere Biology Disorders	13
Progress and Challenges in Survivorship After Acute Myeloid Leukemia in Adults	13
Impact of Germline DNA Repair Mutations on Clonal Hematopoiesis and Myeloid Neoplasm Development	12
Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies	12
Updates in the Classification of T-cell Lymphomas and Lymphoproliferative Disorders	11
Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia	11

Family Planning and Pregnancy in Patients with Chronic Myeloid Leukemia	9
Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies	9
Prevalence and Determinants of Return to Work as a Patient-Centered Outcome in Survivors of Hematopoietic Cell Transplantation	8
Impact of Epigenetic Mutations in Chronic Myelomonocytic Leukemia	8
Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia/Lymphoma	8
Adaptive and Maladaptive Clonal Hematopoiesis in Telomere Biology Disorders	8
CAR-T Cell Therapy: the Efficacy and Toxicity Balance	8
Role of Population Based Studies in Advancing our Knowledge of Myelodysplastic Syndromes	8
Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma	7
An Update on the Management of Advanced Phase Chronic Myeloid Leukemia	7
Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms	7
Pediatric Germline Predisposition to Myeloid Neoplasms	7
Emerging Significance and Implications of a Durable Complete Molecular Remission in the Treatment of Polycythemia Vera	7
Maintenance Therapy Post-Stem Cell Transplantation for Patients with T-Cell Lymphomas	7
Highlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms	6
Approach to the patient with eosinophilia in the era of tyrosine kinase inhibitors and biologicals	6
Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)	6
JAK Inhibitors for Myelofibrosis: Strengths and Limitations	6
Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms	6
Plasmacytoid Dendritic Cell-Expansion in Acute Myeloid Leukemia (pDC‑AML): a Review of Clinicopathologic Features, Genetics, and Outcomes	5
The Evolving Therapeutic Landscape of Richter Transformation	5
Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors	5
Real-world Management of CML: Outcomes and Treatment Patterns	5
Measurable Residual Disease Monitoring in Lymphoma	5
Germline Abnormalities in DNA Methylation and Histone Modification and Associated Cancer Risk	5
Defining Higher-Risk Chronic Myeloid Leukemia: Risk Scores, Genomic Landscape, and Prognostication	5
Managing Survivorship after Hematopoietic Cell Transplantation	4
The Role of Inflammation in CMML Pathobiology and Progression	4
Response-Adapted Therapy for Newly Diagnosed Multiple Myeloma	4
Targeted Therapy for MPNs: Going Beyond JAK Inhibitors	4
A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases	4
Use of Patient-Reported Outcome Measures in Clinical Studies of Chronic Myeloid Leukemia: A Scoping Literature Review	4
Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities	4
NK Cell Therapeutics for Hematologic Malignancies: from Potential to Fruition	4
Use of Patient-Centered Technology and Digital Interventions in Pediatric and Adult Patients with Hematologic Malignancies	4
CML Outcomes and Care Delivery During the COVID-19 Pandemic in Low- and Middle-Income Countries	4